Compare BioNano Genomics Inc (BNGO) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Global E Online Ltd — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Global E Online Ltd trades at $41.19 (market cap $6.87B). The key difference: Global E Online Ltd is far larger — about 502.9× BioNano Genomics Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | GLBE | |
|---|---|---|
Market Cap | $13.66M | $6.87B |
Sector | Health | Technology |
52-Week High | $4.92 | $42.32 |
52-Week Low | $1.06 | $27.54 |
Enterprise Value | $16.26M | $6.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
GLBE trades at $42.08, up 2.26% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS expectations and raising full-year guidance, driven by 39% revenue growth and expanded EBITDA margins. Analyst consensus is unanimously bullish with a $44.75 price target, reflecting confidence in its e-commerce enablement platform.
The stock offers upside potential from robust growth and strategic acquisitions like Passport, but risks include high valuation multiples (P/E of 61.06) and insider selling. Execution on raised guidance and integration of new logistics capabilities are key to sustaining momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
